Herpes Zoster (HZ) is a common painful, debilitating condition caused by reactivation of the varicella-zoster virus. It is characterized by a painful skin eruption which is very complex to treat. Studies have reported that HZ negatively affects Quality of Life (QoL), but no large systematic review on this topic has been published to date. This systematic review aims to summarize the current data on patient-reported QoL amongst patients diagnosed with HZ.
Methods
We searched Medline, Embase, Cochrane Library, CINAHL, and PsycINFO. The primary outcome was the change in percent impairment of QoL compared to normative data. Secondary outcomes were meta-analyses comparing reported QoL to a control group or normative data.
Results
We assessed a total of 536 studies for inclusion. Thirteen studies were included in the systematic review and five studies in the meta-analyses. The total number of patients was 5472.
Conclusions
This systematic review and meta-analysis found lower reported QoL amongst patients diagnosed with acute herpes zoster compared to normative values. Our data show that acute herpes zoster significantly reduces the quality of life of the patients affected.
JohnARCanadayDH. Herpes zoster in the older adult. Infect Dis Clin North Am2017; 31: 811–826.
2.
StrommenGLPucinoFTightRR, et al.Human infection with herpes zoster: etiology, pathophysiology, diagnosis, clinical course, and treatment. Pharmacotherapy1988; 8: 52–68.
3.
JohnsonRWBouhassiraDKassianosG, et al.The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med2010; 8: 37.
4.
YawnBPGildenD. The global epidemiology of herpes zoster. Neurology2013; 81: 928–930.
5.
StudahlMPetzoldMCasselT. Disease burden of herpes zoster in Sweden - predominance in the elderly and in women - a register based study. BMC Infect Dis2013; 13: 586.
6.
HaanpääMLaippalaPNurmikkoT. Pain and somatosensory dysfunction in acute herpes zoster. Clin J Pain1999; 15: 78–84.
7.
GanEY.TianEALTeyHL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol2013; 14: 77–85.
8.
CohenJI. Herpes zoster. New Engl J Med2013; 369: 255–263.
ScholzJFinnerupNBAttalN, et al.The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain2019; 160: 53–59.
11.
GabuttiGBolognesiNSandriF, et al.Varicella zoster virus vaccines: an update. ImmunoTargets Ther2019;8: 15–28.
12.
WutzlerP.BonanniP.BurgessM., et al. Varicella vaccination - the global experience. Expert Rev Vaccines2017; 16: 833–843.
13.
CurranDSchmidt-OttRSchutterU, et al.Impact of herpes zoster and postherpetic neuralgia on the quality of life of germans aged 50 or above. BMC Infect Dis2018; 18: 496.
14.
MoherDLiberatiATetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med2009; 151: 264–269, W64.
15.
TerweeCB.JansmaEPRiphagenII, et al.Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments. Qual Life Res2009; 18: 1115–1123.
16.
Díez-DomingoJCurranDCambroneroMDR, et al.Economic burden and impact on quality of life of herpes zoster in spanish adults aged 50 years or older: a prospective cohort study. Adv Ther2021; 38: 3325–3341.
WellsGSheaBO’ConnellD, et al.The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Ottawa, Canada: The Ottawa Hospital.
19.
SterneJACSavovićJPageMJ, et al.RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019; 366: l4898.
20.
GuyattGHOxmanADVistGE, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008; 336: 924–926.
21.
HozoSPDjulbegovicBHozoI. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol2005; 5. DOI: 10.1186/1471-2288-5-13. Epub ahead of print December 2005.
22.
Review Manager (RevMan). Version 5. 3rd ed.Copenhagen, Denmark: The Cochrane CollaborationThe Nordic Cochrane Centre, 2014.
23.
BeutnerKRFriedmanDJForszpaniakC, et al.Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother1995; 39: 1546–1553.
24.
BouhassiraDChassanyOGaillatJ, et al.Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain2012; 153: 342–349.
25.
BulileteOLeivaARullánM, et al.Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: a double blind, randomized controlled trial. PLoS One2019; 14: e0217335.
26.
DongDSYuXWanCF, et al.Efficacy of short-term spinal cord stimulation in acute/subacute zoster-related pain: a retrospective study. Pain Physician2017; 20: E633–E645.
27.
DroletMBrissonMSchmaderKE, et al.The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J2010; 182: 1731–1736.
28.
KramerSBaeumlerPGeberC, et al.Somatosensory profiles in acute herpes zoster and predictors of postherpetic neuralgia. Pain2019; 160: 882–894.
29.
LiangLLiXZhangG, et al.Pregabalin in the treatment of herpetic neuralgia: results of a multicenter Chinese study. Pain Medicine (Malden, Mass)2015; 16: 160–167.
30.
XuGXuSChengC, et al.Local administration of methylcobalamin and lidocaine for acute ophthalmic herpetic neuralgia: a single-center randomized controlled trial. Pain Pract. DOI: 10.1111/papr.12328. Epub ahead of print 2015.
31.
TangWXuG. Local injection of methylcobalamin combined with lidocaine for acute herpetic neuralgia. Pain Pract2018; 18: 102.
32.
Torcel-PagnonLBricoutHBertrandI, et al.Impact of underlying conditions on zoster-related pain and on quality of life following zoster. J Gerontol A Biol Sci Med Sci2017; 72: 1091–1097.
33.
DuracinskyMPaccalinMGavazziG, et al.ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?BMC Infect Dis2014; 14: 529.
34.
MizukamiASatoKAdachiK, et al.Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in japanese adults aged 60 years or older: results from a prospective, observational cohort study. Clin Drug Investig2018; 38: 29–37.
35.
CurranDOostvogelsLHeinemanT, et al.Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci2019; 74: 1231–1238.
36.
LamCWongCLamE, et al.Population norm of chinese (HK) SF-12 health survey-version 2 of Chinese adults in Hong Kong. Hong Kong Pract2012; 32: 77.
37.
GandekBWareJEAaronsonNK, et al.Cross-validation of item selection and scoring for the SF-12 health survey in nine countries. J Clin Epidemiol1998; 51: 1171–1178.
38.
YangZBusschbachJLiuG, et al.EQ-5D-5L norms for the urban Chinese population in China. Health Qual Life Outcomes2018; 16: 210.
39.
JanssenBSzendeA. Population norms for the EQ-5D. In: SzendeAJanssenBCabasesJ (eds) Self-reported population health: an international perspective based on EQ-5D. Dordrecht, Netherlands: Springer; 2014. http://www.ncbi.nlm.nih.gov/books/NBK500364/(accessed 13 May 2021).
40.
PoderTGCarrierNKouakouCRC. Quebec health-related quality-of-life population norms using the EQ-5D-5L: decomposition by sociodemographic data and health problems. Value Health J Int Soc Pharmacoeconm Outcomes Res2020; 23: 251–259.
41.
ScaloneLCortesiPCiampichiniR, et al.Health related quality of life norm data of the general population in Italy: results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol Biostat Public Health2015; 12: 54. DOI: 10.2427/11457.
42.
EllertUKurthBM. Gesundheitsbezogene lebensqualität bei erwachsenen in Deutschland. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz2013; 56: 643–649.
43.
MatthewsSDe MariaAPassamontiM, et al.The economic burden and impact on quality of life of herpes zoster and postherpetic neuralgia in individuals aged 50 years or older in Italy. Open Forum Infect Dis2019; 6: ofz007.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
